LIPO vs ABBV

For growth investors, Lipella Pharmaceuticals Inc.

(LIPO) is the stronger pick with 19. 3% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate AbbVie Inc. (ABBV) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -99. 5% for Lipella Pharmaceuticals Inc. (LIPO). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus LIPO's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Lipella Pharmaceuticals Inc. 's 1. 77β — meaning LIPO is approximately 423% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), Lipella Pharmaceuticals Inc.

(LIPO) is pulling ahead at 19. 3% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Lipella Pharmaceuticals Inc. grew EPS 22. 2% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, LIPO leads at 27. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -935. 2% for Lipella Pharmaceuticals Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -947. 2% for LIPO. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ABBV (3.

2% yield) pays a dividend. LIPO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Lipella Pharmaceuticals Inc. (LIPO) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, LIPO: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LIPO is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while LIPO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.